Experimental justification of the effectiveness of cord blood stem cell transplantation in chronic myocardial injury
DOI:
https://doi.org/10.34287/MMT.2(41).2019.4Abstract
Purpose of the study. Determination of transplantation efficiency of cord blood stem cells (CB SC) for damage to the myocardium and assessment of the repair of its disturbed functions in the experiment.
Materials and methods. The experiment was conductedonmiceofthe FVBlineattheageof5 months, with a body weight of 25–30 g. Animals were divided into experimental groups of 5 animals in each. The animals of the study group were derived from the experiment before the SC suspension injection, after 2 days, 4 and 8 weeks after cell transplantation.
Results. Analysis of morphofunctional changes after the introduction of cord blood cells in 4 and 8 weeks compared to the original state (3 weeks after modeling of the isoproterenol induced myocardial injury model) has established a clear tendency to improve the investigated parameters. The confirmed phenomenon of self-referral of cord blood nto the lesion zone proves the expediency of transplantation by intravenous injection of a suspension of CB SC. It has been established that transplantation of CB SC causes a temporary deterioration of morphofunctional features, which may be a manifestation of the body's response to xenotransplantation. The CB SC transplantation has a positive effect on the isoproterenol-induced myocardial injury model.
Conclusions: 1. Accumulation of CBSC in the zone of injury after transplantation, proved by experimental research. 2. CB SC transplantation accelerates the processes of myocardial regeneration on the model of injury in laboratory animals. 3. Intravenous injection of the CB SC suspension to the models of myocardial injury proved to be effective. 4. The experimental results obtained can serve as the basis for further clinical studies in patients with heart failure.
References
The Registry of the International Society for Heart and Lung Transplantation (ISHLT), 2017. http://www.ishlt.org/registries/ heartLungRegistry.asp.
Carvalho E, Verma P, Hourigan K, Banerjee R. Myocardial infarction: stem cell transplantation for cardiac regeneration. Regenerative Medicinevol. 2015; 10 (8): 701–705. DOI: org/10.2217/rme.15.63.
Acosta SA, Franzese N, Staples M et al. Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction. Stem Cells. 2013 Jul 1; (Suppl 4). pii: S4–005.
Perin, EC, Dohmann, HF, Borojevic R et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004; 110 (11 Suppl 1): II213–8. DOI:10.1161/01. CIR.0000138398.77550.62.
Wollert KC, Meyer GP, Lotz J, RingesLichtenberg S et al. Intracoronary autologous bonemarrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004; 364 (9429): 141–148. DOI:10.1016/ S0140-6736(04)16626-9.
